Memorial Hospital Research Laboratories
The Kenneth Offit Lab
Research
Professor
Research in the laboratory focuses on the discovery and characterization of novel cancer predisposing genes in humans, including both common and rare variants. We conduct studies to describe phenotype, penetrance, modifying effect, and clinical outcomes associated with germline genetic alterations in cancer patients and their families. In addition, our research focuses on the interpretation and clinical translation of results of massively parallel sequencing of germline genomes in cancer-prone kindreds.
Featured News
Publications Highlights
People
Kenneth Offit, MD
Robert and Kate Niehaus Chair in Inherited Cancer Genomics; Vice Chair, Academic Affairs, Department of Medicine
Professor
- Cancer geneticist Kenneth Offit focuses on gene characterization; genetic and epidemiologic studies of cancer-predisposing alleles; and the therapeutic, prognostic, and psychosocial translation of these findings.
- MD, Harvard Medical School
- [email protected]
- Email Address
- 646-888-4059
- Office Phone
- View physician profile
- Physician profile
Members
- 646-888-3098
- Lab Phone
- 646-888-4058
- Lab Phone
- 646-888-4070
- Lab Phone
- Rashtrasant Tukadoji Maharaj Nagpur University
- University of Texas at El Paso
- University of Bonn
- 646-888-3188
- Office Phone
Lab Alumni
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Bioinformatics Specialist
Career Opportunities
Computational Genetics Fellow
Get in Touch
-
Lab Head Email
-
Office Phone
-
Office Fax
-
Lab Phone
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Kenneth Offit discloses the following relationships and financial interests:
-
AnaNeo Therapeutics
Equity
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].